AZD-2066

N/A

Report date: 2022/07/19 16:22:54
NME

Base Information

Drug NameAZD-2066
Drug Alias NameAZD-2066
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionMetabotropic glutamate receptor 5 antagonists
TargetsMetabotropic glutamate receptor 5
Therapy Area/IndicationsDepressive Disorder, MajorChronic PainPain +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSwedenUnited Kingdom +[4] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesAstrazeneca Plc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAstrazeneca Plc
Active IndicationsN/A
Inactive IndicationsDepressive Disorder, MajorChronic PainPain +[5] 

Other Information

ATC CodeN/A
Related LinksN/A